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Summary
Vitamin D and calcium are essential for normal skeletal growth
and for maintaining the mechanical and structural integrity of
the skeleton. Reduced intake of calcium and vitamin D may be
associated with reduced bone mass and osteoporosis while a
chronic and severe vitamin D deficiency may lead to osteoma-
lacia. 1,25(OH)2D (calcitriol) is the major active metabolite of vi-
tamin D and promotes intestinal calcium absorption and the
mineralization of bone matrix and reduces PTH secretion. De-
spite vitamin D and calcium are considered essential compo-
nents of management strategies for the prevention and treat-
ment of osteoporosis, many people do not have adequate vita-
min D levels. Vitamin D insufficiency is particularly common in
the elderly due to reduced exposition to sunlight, declined syn-
thesis of vitamin D in the skin and impaired renal hydroxyla-
tion. Even though secure inferences from randomized con-
trolled trials on the prevention of osteoporotic fracture with vit-
amin D or its metabolites are limited, these compounds have
been demonstrated to be pharmacologically active, safe and
cost-effective for the prevention of age-related bone loss. Their
use should be encouraged expecially in elderly subjects or in
condition of dietary deficiencies. Interestingly, health benefits
of vitamin D and its analogues may go beyond osteoporosis,
including prevention of cancer and autoimmune diseases and
improvement of neuromuscular function. 
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Introduction
Osteoporosis is the most prevalent metabolic bone disease
among developed countries and it is defined as a skeletal disor-
der characterized by compromised bone strength and increased
risk of fracture (1). Its clinical significance lies in the occurrence
of fractures, involving most commonly the forearm, the vertebral
bodies and the hip, but fractures at other sites may be also asso-
ciated with the disease. For Caucasians, the lifetime risk of an
osteoporotic fracture at 50 years of age has estimated to be ap-
proximately 40% for women and 13% for men (2). Each year
more than 1.5 million people suffer hip, vertebral, and wrist frac-
tures due to osteoporosis, a disease that can be prevented and
treated. The occurrence of osteoporotic fractures leads to con-
siderable mortality, morbidity, reduced mobility and decreased
quality of life (3). Actually, the annual number of hip fractures in
15 countries of European Community (EC) has been estimated
to be 500,000, with a total care cost of about 4.8 billion euros per
year (4). This burden will increase in absolute terms because of
the ageing of the population. Given the magnitude of the prob-
lem, the prevention and treatment of osteoporosis is, therefore,
of major importance for health organizations in all countries.
The major determinant of bone strength and osteoporotic fracture
risk is bone mineral density (BMD), as assessed by dual photon
absorptiometry or dual energy x-ray absorptiometry. According to
WHO criteria, osteoporosis is defined to exist when BMD values
fall more than 2.5 standard deviations below the young adult ref-
erence mean (1). Many studies indicated that the risk of fragility
fractures increases progressively as BMD declines (5-8). It has
been estimated that the risk of new vertebral fractures increases
by a factor of 2.0-2.4 for each standard deviation decrease in
BMD, irrespective of the site of bone density measurement (8).
However, bone strength depends not only on BMD. Bone size as
well as bone quality are other important components that interact
with BMD in determining the risk of fracture (1).
Skeletal bone mass is determined by a combination of endoge-
nous (genetic, hormonal) and exogenous (nutritional, physical
activity) factors. In adolescence to attain the optimal peak bone
mass the main determinants are genetic, nutritional and behav-
ioural (exercise). In adult and elderly populations the main deter-
minants of age-related bone loss are represented by the gonadal
status, by the influence of some nutrients and by the physical ac-
tivity. Both a low peak bone mass and a high rate of bone loss
represent risk factors for osteoporosis and osteoporotic frac-
tures. Nutrition plays an important role in bone health. The two
nutrients essential for bone health are calcium and vitamin D,
even though an adequate nutritional intake of nutrients and a
regular exercise are also necessary (9, 10). Vitamin D and calci-
um are important for normal skeletal growth and for maintaining
the mechanical and structural integrity of the skeleton. Reduced
supplies of calcium may be associated with a reduced bone
mass and osteoporosis, whereas a chronic and severe vitamin D
deficiency leads to osteomalacia, a metabolic bone disease
characterized by a decreased mineralization of bone matrix and
an increased osteoid volume. Vitamin D deficiency can be con-
firmed by measuring the serum concentration of 25-hydroxy-vita-
min D [25(OH)D], which is the major circulating metabolite and
represents the storage form of vitamin D. In patients with osteo-
malacia, serum 25(OH)D levels are usually below 5-6 ng/ml and
often undetectable (10-12). Biochemically osteomalacia is char-
acterized by normal or low serum concentrations of calcium and
phosphate, and increased activity of alkaline phosphatase. Vita-
min D deficiency is common in the elderly, particularly in institu-
tionalised subjects. The major causes of vitamin D deficiency are
a scarce exposition to sunlight, a decline in the synthesis of vita-
min D in the skin, a poor nutrition, and a decreased renal hy-
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droxylation of vitamin D (12). A subclinical vitamin D deficiency,
is also common with ageing. This condition, that has been de-
fined vitamin D insufficiency (10, 11), is increasingly being recog-
nized as a distinct pathological skeletal entity, characterized by
normocalcemia and normal bone mineralization and by an in-
crease in circulating levels of parathyroid hormone (PTH). In the
presence of osteoporosis, vitamin D insufficiency may amplify
bone loss and thus enhance fracture risk. It follows that at any
age, but particularly in postmenopause and in the elderly, an ad-
equate intake of both calcium and vitamin D, is important for the
preservation of bone mass and prevention of osteoporosis (10,
13, 14).
Vitamin D and bone homeostasis
Vitamin D is important for bone, for its essential role in promot-
ing intestinal calcium absorption and mineralization of bone
matrix. The major source of vitamin D is the skin, where it is
produced by the action of ultraviolet light on steroid precursors.
Vitamin D is also present in a limited number of foods, and the
dietary sources of the vitamin can be important under circum-
stances of decreased sunlight exposure. Dietary vitamin D is
absorbed in the small intestine via the intestinal lymphatic sys-
tem in the presence of bile acids. Vitamin D is derived from
plant (vitamin D2 or ergocalciferol) and animal sources (vitamin
D3 or cholecalciferol). The main dietary sources of vitamin D
are fatty fish (salmon, sardines, tuna) and oils derived from
them, some meat products (liver), eggs and wild mushrooms.
Vitamin D (D3 and D2 collectively) is not a true vitamin, but a
pro-steroid hormone that is biologically inert until metabolised.
It is transported to the liver bound to a specific α-globulin (vita-
min D binding protein), and to a small extent albumin and
lipoproteins. In the liver, vitamin D is metabolised to 25(OH)D,
which functions as the major storage form by virtue of its long
half-life. In the kidney 25(OH)D (25-hydroxy-cholecalciferol) is
further metabolised by a 1α-hydroxylase enzyme to 1,25(OH)2D
(calcitriol), the hormone responsible for the biological effects of
vitamin D. Metabolism of vitamin D may be even more com-
plex, since recent studies demonstrated the existence of ex-
trarenal 1α-hydroxylases in many tissues, including bone and
muscle (15). Locally produced 1,25(OH)2D may therefore act
as a paracrine/autocrine factor. The binding of calcitriol to the
vitamin D receptor (VDR), a nuclear steroid hormone receptor,
activates VDR to interact with retinoid X receptor (RXR) and
form the VDR/RXR/co-factor complex, which binds to vitamin D
response elements in the promoter region of target genes to
regulate gene transcription (16). These receptor are located in
classical target tissues including bone, intestine, kidney and
parathyroid glands as well as in many other tissues or cell
types such as skin, muscle, and the immune system (16, 17).
Although the classical genomic pathway is responsible of most
biological activity of vitamin D, some effects may be mediated by
cell surface receptors through non-genomic pathways (18, 19). 
Calcitriol is the major biologically active metabolite of vitamin D.
The principal regulators of 1,25(OH)2D production are PTH,
1,25(OH)2D itself, dietary intake of calcium and phosphate.
There are three primary target organs for circulating 1,25(OH)2D:
intestine, parathyroid gland and bone. In the intestine, calcitriol
induces the expression of an epithelial calcium channel, calcium-
binding protein (calbindin), and a variety of other proteins to help
the transport of dietary calcium into the circulation (20). In the
skeleton, calcitriol influences bone remodeling, mainly by acting
on osteoblasts, in which it stimulates the production of osteocal-
cin and different cytokines (21-23). VDRs have been identified in
osteoblasts and in several osteoblastic cell lines while their pres-
ence in osteoclasts is still under debate (24). In the parathyroid
glands, 1,25(OH)2D markedly decreases PTH gene transcription
and parathyroid cell proliferation and induces parathyroid cell dif-
ferentiation (25, 26). Thus, the overall effects of 1,25(OH)2D on
mineral metabolism may be summarized as: 1) increased intesti-
nal calcium absorption, leading to increase in serum calcium; 2)
decreased of serum PTH level (both through direct inhibition of
PTH secretion from the parathyroid gland and indirect inhibition
of PTH secretion by the raised serum calcium levels); 3) de-
creased bone resorption (mainly due to a reduction in the PTH-
mediated bone resorption); and 4) under certain conditions in-
creased bone formation (27). Usually, under normal vitamin D
status, the small intestine absorbs about 30% of dietary calcium.
In the absence of calcitriol, intestinal calcium absorption is solely
by the passive, extracellular route, which limits gross calcium ab-
sorption to about 10-15% of intake. 
The vitamin D status may be evaluated by measuring the serum
concentration of 25(OH)D, the main circulating form of vitamin D.
Since 25(OH)D concentrations are mainly affected by sunlight ex-
posure and intensity (28), the two major determinants of serum
25(OH)D levels are the season and the geographical location. In
fact, the cutaneous synthesis of previtamin D is maximal in sum-
mer and minimal in winter (Fig. 1), and an inverse association ex-
ists between mean 25(OH)D concentration and latitudes. There is
no general consensus on normal serum 25(OH)D values (29).
Clearly, reference levels of vitamin D will depend on the age, skin
pigmentation, season, latitude and sun exposure of the popula-
tion studied. Moreover, variation among different assays and
among different laboratories using the same assay have been
described (30, 31). Several studies have been performed to es-
tablish a threshold of normal 25(OH)D levels in different popula-
tions based on an increased risk of secondary hyperparathy-
roidism, low BMD or high bone turnover. Even though these
threshold estimates varied among different studies there is com-
mon opinion that in healthy adult subjects the optimal serum
25(OH)D level for bone health is approximately 30 ng/ml (75
nmol/l) (11, 32). When serum 25(OH)D values fall below this
threshold, there is a progressive increase in PTH secretion (11,
33) that may increase bone resorption. Moreover, it has been es-
timated that 25(OH)D levels below 32 ng/ml (80 nmol/l) are asso-
ciated with decreased calcium absorption (33). A long-lasting and
severe deficiency of vitamin D, as defined by a serum level of
25(OH)D lower than 6 ng/ml (15 nmol/l), is associated with defec-
tive mineralization resulting in rickets in children and osteomala-
cia in adults. Vitamin D insufficiency, the preclinical phase of vita-
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Figure 1 - Annual variations of 25-(OH) serum levels in healthy subjects
with age range between 66 and 95 years (adapted from Lorè F et al.,
Italian Journal of Mineral and Electrolyte Metabolism. 1988;2:93-106).
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min D deficiency, as defined by a serum level of 25(OH)D com-
prised between 6 and 30 ng/ml, causes a reduced calcium supply
and a secondary hyperparathyroidism. If this state remains chron-
ic, osteopenia results. In addition to its role in calcium homeosta-
sis several data suggested a direct effect of vitamin D on muscle
strength and low serum 25(OH)D levels have been also associat-
ed with neuromuscular consequences, including lower extremity
muscle weakness and increased risk of falling (34, 35).
Calcium, vitamin D and osteoporosis
Calcium and vitamin D are recognized as essential nutrients
throughout life for skeletal growth and maintenance of bone
mass. Calcium is the prevalent mineral of bone and its absorption
from the intestine depends on vitamin D. Convincing evidence
has been given that dietary calcium intake is positively related to
BMD in children and adolescents (36). In adolescent, the higher
the calcium intake, the greater the peak bone mass (37). A posi-
tive correlation between bone mass and calcium intake has been
demonstrated also in adult (38, 39). Although there are many fac-
tors which modulate the progression of age-related bone loss
syndromes, the pathogenesis of this process has been attributed,
at least in part, to decreased calcium absorption by an “aging in-
testine”, to an associated elevation in circulating PTH, and to de-
creased synthesis of 1,25(OH)2D (13, 40). Decreased 1,25(OH)2D
synthesis by the aging kidney results from both age-related pro-
gressive loss in the capacity of the renal 1-α-hydroxylase to re-
spond to progressive elevation in PTH and an age-related de-
crease in the circulating 25(OH)D precursor (40). Women with
osteoporosis have been often demonstrated to be characterized
by reduced intestinal calcium absorption when compared with
age-matched control subjects (39, 41). This abnormality is partic-
ularly relevant in those women who have a low calcium diet.
Moreover, increments in serum osteocalcin levels observed in
humans treated with 1,25(OH)2D, and animal studies demonstrat-
ing increased number of bone marrow osteoblast precursors dur-
ing 1,25(OH)2D administration are consistent with the hypothesis
that abnormalities in the production and skeletal distribution of
1,25(OH)2D may also contribute to the defects in osteoblast func-
tion and bone formation (42, 43). Dietary calcium and vitamin D
intake as well as solar exposure generally decreases with in-
creasing age, and the dermal production of vitamin D following a
standard exposure to UVB light can be impaired in elderly sub-
jects, due to atrophic skin changes (29, 44). Moreover, several
epidemiological studies, performed in different populations,
demonstrated that a low vitamin D status is common among adult
(11, 13, 45, 46) and elderly (47-49) populations, regardless of lati-
tude. All these changes in vitamin D metabolism render the age-
ing population at higher risk of vitamin D deficiency, especially in
winter seasons and may lead to severe consequences in terms of
fall, osteoporosis and fractures (Fig. 2). Importantly, both type I
(postmenopausal) and type II (senile) osteoporosis appear to be,
at least in part, related to primary and secondary abnormalities of
vitamin D-endocrine system (50). Similar abnormalities have
been also described in corticosteroid-induced osteoporosis, the
most common cause of secondary osteoporosis (51). Recently,
the observation that VDR genotypes may be predictive of differ-
ences in bone mass and intestinal calcium absorption in post-
menopausal women adds further complexity to this issue (52-54).
Some subjects may be in fact genetically predisposed to impaired
calcium homeostasis and could be particularly sensitive to reduc-
tion in calcium intake and/or vitamin D levels. 
In the last decade, a positive association between serum
25(OH)D concentrations and bone mass has been reported in
adult and elderly populations from North America and Europe.
Several studies have shown a relationship between BMD, vitamin
D insufficiency and secondary hyperparathyroidism in the elderly
(55, 56) but also in postmenopausal and middle-aged women
(57, 58). In a cross-sectional study conducted in the UK a positive
relation between serum 25(OH)D values and BMD was observed
in a group of middle-aged women (58). In an American study per-
formed in postmenopausal women with low vertebral bone mass,
a relation between vertebral BMD and PTH values was found on-
ly in subjects with low 25(OH)D values (57). In another study a
significant association between low femoral BMD and low
25(OH)D levels was described in normal women older than 60
years (55). A more recent study in 13,432 men and women from
the NHANES III cohort (age > 20 yrs), serum 25(OH)D and total
hip BMD were positively associated up to 25(OH)D levels of 90 to
100 nmol/l (59). An increased risk of fracture with low levels of vit-
amin D and reduced risk with vitamin D supplementation has
been observed in many but not all studies (10, 13). It has been
estimated that individuals with 25(OH)D levels below 68 nmol/L
have a 4 time increased fracture risk over 8 years, independently
of BMD. This risk further increases, reaching 19 times in patients
with osteoporosis (60). Furthermore, women with acute hip frac-
ture showed markedly reduced bone levels of 1,25(OH)2D as well
as reduced circulating 25(OH)D levels (Fig. 3) with respect to
controls in different studies (61-63).
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Figure 2 - Schematic representation of the relationships between calci-
um, vitamin D endocrine system and bone loss.
Figure 3 - 25(OH)D levels in women with and without acute hip frac-
tures (adapted from Nuti et al., Clin Orthop. 2004;422:208-213). 
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Vitamin D and its metabolites in the treatment 
of osteoporosis
Relatively small changes in vitamin D status may have signifi-
cant effects on bone mass. This justifies the use of vitamin D
and its active metabolites in the prevention and treatment of
osteoporosis, since vitamin D deficiency or insufficiency has
been found to be frequent in the elderly as well as in post-
menopausal women, particularly during low sun exposure. 
Treatment with vitamin D
The most rational approach to reducing vitamin D insufficiency
is supplementation. It has been estimated that the body uses
on average 3,000-5,000 IU daily of cholecalciferol (64). Even
though both vitamin D2 and D3 can be used, ergocalciferol is
only about 20-40% as effective as cholecalciferol in maintain-
ing serum 25(OH)D concentrations, since is more rapidly ca-
tabolized (65). Fortification of foods with vitamin D provides an
alternative approach to direct supplementation. This approach
is common in the US, where milk is fortified with vitamin D, and
less common in Europe with the exception of some Northern
countries (Belgium, Netherlands and United Kingdom) where
fortification is compulsory only to margarines (66). In Europe,
the recommended dietary allowances (RDA) for vitamin D have
been proposed in 1998 by the report on osteoporosis-action on
prevention (66). The requirement for dietary vitamin D, based
on European and Nordic recommendations, depends on the
amount of sunshine exposure, with an higher limit estimated
for individuals with minimal endogenous synthesis and a lower
limit for individuals able to produce adequate vitamin D. How-
ever, a common RDAs of 400 IU (10 mg) daily has been pro-
posed for people aged 65 years or over (66). Even though a
similar RDA of 400 IU irrespective of age is also established by
the US Food and Drug Administration, the proposed Institute of
Medicine Adequate Intake (AI) for the US and Canada is 400
IU daily for subjects 70 years or younger, and 600 IU (15 mg)
daily for those over age 70 years (67-70). Importantly a daily
intake of 600 IU of vitamin D3 is needed to reach a mean
serum 25(OH)D level of 50 nmol/l and at least 800-1000 IU
(20-25 mg) is needed to attain a mean level of 75 nmol/l, that is
close to the suggested threshold for optimal skeletal health
(32). Thus, according to these recent evidences, higher vitamin
D intakes than those currently recommended by RDAs and AI
should be advised, especially in the elderly or other high-risk
populations. As counterpart, excess vitamin D intake should be
also avoided. Although the maximum safe dose is still un-
known and doses of 4000 IU daily have been given without
toxicity (71, 72), intakes of 50 mg (2000 IU) daily should not be
exceeded to avoid some harm full effects, such as hypercal-
cemia and hypercalciuria (73, 74). 
Some randomised controlled prospective studies and recent
meta-analyses confirmed the role of calcium and vitamin D
supplementation in the prevention of bone loss and osteoporo-
sis, even though they differed in baseline calcium and vitamin
D status, in age range or in study design (75, 76). Importantly,
as concluded by a recent Cochrane review (76) the relative
contribution of vitamin D and calcium to these benefits was
less clear. Although longitudinal data have suggested a role of
vitamin D intake in modulating bone loss in peri- and post-
menopausal women, most of the studies of vitamin D and cal-
cium supplementation have failed to support a significant effect
of vitamin D and calcium during early menopause. In a 2 year
double-blind study on early postmenopausal women (mean
age 57 yrs), whose average baseline serum 25(OH)D concen-
tration was well within the normal range, the addition of 10,000
IU vitamin D weekly to calcium supplementation at 1000
mg/day did not confer benefits on BMD beyond those achieved
with calcium supplementation alone (77). Similarly, in a ran-
domized, co-twin, placebo-controlled, double-blind study in
early postmenopausal twin pairs, vitamin D supplementation
(800 IU/day) as a single agent for 2 years was not effective on
BMD and bone markers (78). In contrast, a more recent dou-
ble-blind, randomised, 30-month controlled trial in 120 peri-
(age range 45-50 yrs) and early (age range 50-55 yrs) post-
menopausal women showed a positive effect of calcium and vi-
tamin D supplementation (Ca 500 mg and vitamin D 200 UI,
daily) on BMD change with respect to placebo (79). In another
study in healthy postmenopausal women and men (mean age
57.9±11 yrs) supplementation with oral vitamin D (500 IU) and
calcium during winter abolished seasonal changes in cal-
ciotropic hormones and markers of bone turnover, leading to
an increase in BMD with respect to placebo (80). There is a
clearer skeletal benefit in vitamin D and calcium supplementa-
tion in older postmenopausal women. Vitamin D intake be-
tween 500 and 800 IU daily, with or without calcium supple-
mentation, has been shown to increase BMD in Caucasian
women with a mean age of approximately 60-70 years. Con-
versely, in a study in calcium-replete postmenopausal African
American women there was no observed effect of vitamin D3
supplementation (800 IU/day) for 2 years on bone loss or bone
turnover markers (81). In Caucasian women older than 65 as
well as in elderly men, there is even more benefit. This latter
point has been clearly addressed by a number of studies on
the effects of vitamin D supplementation on bone loss in the el-
derly. Some studies have been performed with vitamin D
alone, some others with vitamin D and calcium supplementa-
tion (82-84). It appears from these studies that supplementa-
tions with daily doses of 400-800 IU of vitamin D, given alone
or in combination with calcium (1200-1500 mg daily), are able
to reverse vitamin D insufficiency, to reduce secondary hyper-
parathyroidism, to prevent bone loss and to improve bone den-
sity in elderly subjects (10, 13, 73). Beneficial effects on BMD
seems greater at the femoral neck than lumbar spine or fore-
arm (84). Of interest, a positive and significant effect on BMD
has been observed within the first year of treatment in a ran-
domized, double-blind, placebo-controlled study on elderly
women with vitamin D deficiency, defined as serum 25(OH)D
concentrations  12 ng/ml (85). Moreover, both vitamin D
alone (vitamin D2 300,000 IU single injection or oral vitamin D3
800 IU/day) and vitamin D associated with calcium resulted in
a small but significant improvement in BMD, suppressed
parathyroid hormone, and reduced falls as compared to con-
trols in a recent secondary prevention study (86).
Even though most studies documented a positive effect on
BMD, the role of vitamin D supplementation on fracture risk is
still controversial (Fig. 4). In a retrospective epidemiological
case-control study conducted in six European Mediterranean
countries (MEDOS study) treatment with vitamin D was report-
ed to be associated with a slight but not significant reduction in
the incidence of hip fracture (87). Randomized controlled trials
showed conflicting results. A systematic meta-analysis indicated
that a clear reduction in hip (pooled RR 0.74, 95% CI 0.61-0.88)
and non-vertebral (pooled RR 0.77, 95% CI 0.68-0.87) fracture
risk of vitamin D at doses of 700-800 IU/day, but not at 400
IU/day (88). However, the relative effect of vitamin D alone or
vitamin D plus calcium was not investigated. A more recent
meta-analysis (89) showed no statistically significant effect of vi-
tamin D alone on hip fracture (seven trials, 18,668 participants,
RR 1.17, 95% CI 0.98 to 1.41), vertebral fracture (four trials,
5698 participants, RR – random effects 1.13, 95% CI 0.50 to
2.55) or any new fracture (eight trials, 18,903 participants, RR
0.99, 95% CI 0.91 to 1.09). Conversely, vitamin D with calcium
marginally reduced hip fractures (seven trials, 10,376 partici-
26 Clinical Cases in Mineral and Bone Metabolism 2006; 3(1): 23-34
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pants, RR 0.81, 95% CI 0.68 to 0.96), non-vertebral fractures
(seven trials, 10,376 participants, RR 0.87, 95% CI 0.78 to
0.97), but there was no evidence of effect of vitamin D with cal-
cium on vertebral fractures. The effect appeared to be restricted
to those living in institutional care. The first prospective, large,
multicenter, randomised, double-blind, placebo controlled study
was performed on a French cohort of over 3000 institutionalised
elderly women (mean age 84 years) during treatment with either
vitamin D (800 IU/day) and calcium (1.2 g/day) or placebo for
three years (90). Active treatment significantly reduced the inci-
dence of new hip fractures by 29% and that of all non vertebral
fractures by 24% (90). Similar results on hip fracture prevention
(RR 1.6; 95% CI 0.96-3.0) were obtained in a multicenter, ran-
domised, double-masked, placebo-controlled confirmatory
study on 583 French ambulatory institutionalised women (mean
age 85.2 years) (91) as well as in a placebo-controlled trial of
the effect of calcium (500 mg/day) and vitamin D (700 IU/day) in
healthy community-based men and women older that 65 years
(82). After three years 12.9% of subjects treated with placebo
and 5.9% of those treated with vitamin D and calcium sustained
non-vertebral fractures, a statistically significant difference (82).
Moreover, two different studies showed that vitamin D3 treat-
ment by itself at doses of 100,000 IU every 4 months (92) or
30,000 IU annually (93) reduces the occurrence of fractures in
elderly subjects. Lower vitamin D doses showed no significant
reduction in fracture rate (94, 95). In a Dutch study, the adminis-
tration of 400 IU daily of vitamin D to elderly subject with a high
calcium intake produced no reduction in fracture rate (94). Simi-
larly, intervention with 400 IU daily of vitamin D3 failed to pre-
vent either hip or vertebral fractures over a 2-year people in a
nursing home population (95). Despite these positive results, re-
cent reports from three large clinical trials, raised major con-
cerns about the role of vitamin D supplementation on fracture
prevention (96-98). The first was a randomized placebo-con-
trolled trial performed in 5,292 elderly people (70 years or older)
who had had a low trauma fracture before being enrolled (96).
Treatment with calcium (1000 mg/day) and vitamin D3 (800
IU/day), either alone or in combination, for at least 24 months
was not effective in secondary prevention of further fractures
with respect to placebo. A second study on a larger sample of
36,282 postmenopausal women enrolled in a Women’s Health
Initiative clinical trial recently analyzed the role of long term (av-
erage follow-up period 7 yrs) calcium (1000 mg/day) and vita-
min D3 (400 IU/day) supplementation for primary prevention of
hip and other fractures (97). Despite a small but significant in-
crease in total hip BMD, no significant reduction in hip fracture
risk was observed in calcium and vitamin D group with respect
to placebo (12% reduction, hazard ratio 0.88, 95% confidence
intervals 0.72-1.08). Similarly no significant reductions in clinical
vertebral, wrist or total fractures were reported. Moreover, there
was a small but significant increase in kidney stones in women
treated with calcium and vitamin D with respect to placebo (haz-
ard ratio 1.17, 95% confidence intervals 1.02-1.34), that ap-
peared to be unrelated to high baseline calcium intake. It is con-
ceivable that the effect of calcium and vitamin D supplementa-
tion on fracture reduction might require higher doses of vitamin
D than the 400 IU used in this study. Adherence to treatment
might also be considered. Of interest, 41% of women didn’t take
the intended dose and in secondary subgroup analysis, the pre-
ventive effect on hip fracture was greater and significant in
women who adhered to the treatment regimen (29% reduction,
hazard ratio 0.71, 95% confidence intervals 0.52-0.97) as well
as in women over 60 years of age and women not taking per-
sonal calcium supplements (97). In the third study, higher doses
of vitamin D (800 IU/day) with calcium (1000 mg/day) were giv-
en for 18-42 months to 3,314 elderly women with one or more
risk factors for hip fracture (98). After a median follow-up of 25
months the occurrence of fracture was lower than expected but
not significantly differed with respect to placebo. 
Finally, although the possible effects of calcium and vitamin D
in fracture prevention are generally attributed to increases in
BMD, it has also been hypothesized that supplementation
might increase muscular strength, thereby reducing the risk of
falls (34, 35). In a study involving a group of 122 elderly institu-
tionalised women, 50% of whom had vitamin D insufficiency,
musculoskeletal function was shown to improve significantly)
after 3 months’ therapy with calcium and vitamin D, while there
was no significant improvement in women treated with calcium
alone (99). The incidence of falls in the women who received
calcium and vitamin D was reduced by 49%. Likewise, Pfeifer
and colleagues observed a reduction in body sway and a re-
duction in falls with short-term calcium and vitamin D supple-
mentation as compared with calcium alone in a sample of 148
elderly women (100).
Taken all together, these studies underline the need for an ad-
equate vitamin D and calcium nutrition in the elderly, particular-
ly in individuals living indoors in nursing homes, who have a
high prevalence of vitamin D deficiency or insufficiency. 
Treatment with active vitamin D metabolites
The 1α-hydroxylated forms of vitamin D, 1,25-dihydroxychole-
calciferol or calcitriol, and 1α-hydroxy-cholecalciferol or alfacal-
cidiol, have been proposed as possible therapies for osteo-
porosis (101, 102). Both compounds strongly stimulate the in-
testinal calcium absorption, and the response is dose-depen-
dent (Fig. 5). This leads to a suppression of PTH secretion and
a decrease in bone turnover. Over the past two decades, sev-
eral clinical trials have been performed in osteoporotic patients
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Figure 4 - Relative risk with 95% interval of confidence of vertebral frac-
tures after treatment with standard vitamin D compounds (with and
without calcium supplementation). Major randomized, double blind con-
trolled studies have been considered.
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using calcitriol or alfacalcidiol, at doses from 0.25 to 2.0
μg/day. A positive effect of both compounds on BMD was seen
in some clinical trials, whereas in others there was no change
in BMD (13, 50, 103). In addition, there is not yet a definite an-
swer as to whether these compounds decrease the incidence
of osteoporotic fractures. A meta-analysis on published ran-
domised controlled trials showed a consistent, statistically sig-
nificant effect of hydroxilated vitamin D compounds in all BMD
sites for doses above 0.43 mcg, with an overall effect that was
higher than that of standard vitamin D treatment (75). A more
recent meta-analysis revised the overall effect of active vitamin
D metabolites (alfacalcidiol and calcitriol) on BMD and fracture
rate (104). A global effect in preventing bone loss in patients
not exposed to corticosteroids was demonstrated. Moreover,
active vitamin D metabolites significantly reduced the overall
fracture rate (RR 0.52, 95% CI 0.46-0.59) and both vertebral
(RR 0.53, 95% CI 0.47-0.60) and non-vertebral (RR 0.34, 95%
CI 0.16-0.71) fracture rate, respectively (104). The therapeutic
effects seem to be pharmacological rather than physiological,
and some concern exists about the potential side effects of this
treatment. Hypercalcemia and impairment of renal function are
rare with lower doses (up to 0.5 μg/day) but more frequent with
higher doses (1-2 μg/day). For these reasons, treatment with
calcitriol or alfacalcidiol necessitates monitoring of serum calci-
um and renal function, unlike treatment with vitamin D. 
A number of clinical trials have been conducted over the past
few years with the aim of verifying the efficacy of calcitriol in
postmenopausal and involutional osteoporosis (105-113). Due
to differences in studies design a dosage used these studies
led to conflicting results, with bone mass and vertebral fracture
rate reported as improving in some studies but remaining un-
changed or worsening in others. One of the most likely expla-
nations for the negative results is that these studies used inef-
fective doses, because it seems that the efficacy of 1 α-hydrox-
ylated vitamin D3 compounds is dose-related. It is now more
widely appreciated that the window of efficacy for calcitriol is
quite narrow (101-103). Whereas 0.4 μg/day may be insuffi-
cient for increasing calcium absorption in many patients, a
dose of 0.5 μg/day or higher is effective in nearly all patients
with an appropriate supply of dietary calcium (not higher than
0.8 μg/day so as not to increase to the risk of hypercalcemia).
Using dosages ranging from 0.5 to 0.8 μg/day, calcitriol has
been shown to increase total body and spine BMD in studies
on postmenopausal women (103). However, there are few data
yet on the effect of calcitriol on fracture incidence (Fig. 6). A
significant effect on vertebral fracture rate was obtained in one
study (105), while another showed a positive but not significant
trend (106). In the former study, 0.5 μg calcitriol per day de-
creased the incidence of vertebral fractures in women with
postmenopausal osteoporosis and with fewer than five frac-
tured vertebrae, but not in those with more than five fractured
vertebrae (106). A more recent double blind randomised trial
investigated the effect of calcitriol or oestrogen therapy on
BMD and the incidence of falls and fractures (107). A reduced
incidence of falls and non vertebral fractures over a 3 years pe-
riod was demonstrated in the calcitriol and oestrogen plus cal-
citriol groups with respect to placebo. 
In addition to its role in postmenopausal and involutional osteo-
28 Clinical Cases in Mineral and Bone Metabolism 2006; 3(1): 23-34
L. Gennari et al.
Figure 5 - Fractional radiocalcium absorption (fx) during long term treatment with calcitriol or alfacalcidiol in postmenopausal osteoporotic patients.
Dotted lines indicate the normal range (adapted from Caniggia A et al., Osteoporosis Int. 1993;1:S181-S185).
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porosis, calcitriol was used in the treatment of secondary os-
teoporosis, especially corticosteroid-induced osteoporosis
(104, 114, 115) and post-transplantation bone loss (116-120).
Corticosteroids result in impaired gastrointestinal absorption of
calcium and increased urinary calcium loss leading to sec-
ondary hyperparathyroidism with enhanced bone resorption, as
well as having direct inhibitory effects on osteoblasts and bone
formation. However, even though vitamin D analogs were
found to be active in preventing hip and spinal bone loss in cor-
ticosteroid induced osteoporosis, their effect appear lower than
that observed with bisphosphonates (115) and further data are
required regarding fracture prevention in patients receiving glu-
cocorticoid therapy (121). The mechanism of action of calcitriol
in preventing transplant osteoporosis may be related to effects
on either corticosteroid or cyclosporine pathways, especially
secondary hyperparathyroidism, or to its immunomodulatory
properties with consequent immunosuppressive agent sparing
(116). Recent clinical trials also suggest an important future
role of calcitriol as adjunctive therapy to bisphosphonates and
estrogen in the treatment of osteoporosis. In particular, a sig-
nificant benefit of calcitriol treatment combined with HRT on
BMD at different skeletal sites has been demonstrated in post-
menopausal women (109, 122). 
Alfacalcidiol is a synthetic precursor of 1,25(OH)2D3 that has to
be converted into 1,25(OH)2D3 predominantly by vitamin D 25-
hydroxylase before to exert its biological effects. This activation
takes places even with advanced liver disease. Because of
these pharmacokinetic aspects, alfacalcidiol is characterized by
a more safe profile with respect to calcidiol as regard the risk of
developing hypercalcemia or hypercalciuria. This active vitamin
D analogue is a pharmacologically active compound, which acts
independently of vitamin D status (101, 102, 104, 123). Alfacal-
cidiol was initially synthesized in order to treat the bone disease
of patients with chronic renal disease more effectively since the
renal 1α-hydroxylation of 25(OH)D3 was compromised in these
individuals (124). Subsequently, observations showed that os-
teoblasts contain a 25-hydroxylase enzyme which converts 1αO-
HD3 into 1,25(OH)2D3, and that there are higher skeletal concen-
trations of 1,25(OH)2D3 after 1αOHD3 administration than after
1,25(OH)2D3 despite the fact that serum levels of 1,25(OH)2D3
were lower after 1αOHD3 than after 1,25(OH)2D3 administration
(123). Thus, a small proportion of administered alfacalcidiol may
be directly activated in bone by a 25-hydroxylase expressed by
osteoblasts, suggesting a localised autocrine or paracrine effect
in bone tissue, in addition to the systemic effects. In vivo and in
vitro experimental evidences suggested that alfacalcidiol not on-
ly normalizes PTH and suppresses bone resorption but also si-
multaneously stimulates bone formation (125). Alfacalcidiol was
demonstrated to improve intestinal calcium absorption in osteo-
porotic women and has been utilized to treat osteoporosis for
more than 20 years in Japan (126-128). In different studies, this
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Figure 6 - Relative risk with 95% interval of confidence of vertebral fractures after treatment with active vitamin D metabolites (calcitriol or calcidiol
with and without calcium supplementation). Major randomized, double blind controlled studies have been considered.
Figure 7 - Lumbar BMD changes from baseline during treatment with alfa-
calcidiol or vitamin D plus calcium (adapted from Nuti et al., Rheumatol Int.
2006;26:445-453).
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compound was demonstrated to maintain BMD, and prevent the
occurrence of osteoporotic fractures. Positive effects on bone
turnover and lumbar (Fig. 7), femoral neck, or radial BMD have
been reported with alfacalcidiol doses ranging from 0.5 to 1.0 μg
in both early and late postmenopausal women (129-132). There
is now some evidence that alfacalcidiol may be particularly ac-
tive in conditions characterized by an increased rate of bone loss
(133, 134). Alfacalcidiol 1 μg/day fully prevented vertebral bone
loss over 3 years in women after the first year of menopause
(133). Moreover, improvement in bone turnover, increase in
BMD, and reduction in fracture rates have been described during
alfacalcidiol treatment in corticosteroid-induced osteoporosis
(135, 136), in inflammation-induced bone loss (137, 138), in pa-
tients following end organ transplant (139) and in patients with
chronic renal failure (140). Importantly, recent clinical compara-
tive studies suggested an increased efficacy of alfacalcidiol over
vitamin D in the treatment of postmenopausal (132) and gluco-
corticoid induced osteoporosis (141, 142). Compared to plain vit-
amin D, alfacalcidiol exerts higher bone-protective effects, thus
allowing the doses to be minimized and lowering the risk of ad-
verse effects, including hypercalcemia. Notwithstanding these
observations, the anti-fracture efficacy of this compound remains
currently doubtful, since variable results for bone loss and frac-
tures reduction have been demonstrated in different trials vary-
ing according to their designs, methodologies, and outcomes
(Fig. 6). In particular, bone loss and fracture prevention at the hip
level, while being the most invalidating outcome of osteoporosis,
remain under-investigated in long-term randomized controlled tri-
als (104). Moreover, its efficacy with respect to other treatment
regimens in osteoporosis (i.e. bisphosphonates) also remains to
be fully elucidated. While a study in postmenopausal women in-
dicated that switching to 1α-hydroxycholecalciferol therapy after
short-term HRT permitted maintenance of increase in bone
mass due to HRT for at least 18 months (143), other studies
demonstrated a lower efficacy of alfacalcidiol with respect to bis-
phosphonates or calcitonin (144, 145). Conversely, several stud-
ies demonstrated that alfacalcidiol may be an excellent partner
for combination therapy (i.e. with HRT) to improve the antifrac-
ture efficacy, especially in elderly patients (146-150).
Among the multiple pleiotropic effects of alfacalcidiol its posi-
tive action on muscle strength and neuromuscular coordination
may exert an important and additional role in fracture risk re-
duction (151). Treatment with alfacalcidiol in elderly people sig-
nificantly decreased the high risk of falls (152, 153). Moreover,
the effect of alfacalcidiol in increasing the number and diame-
ter of type 2 fibre muscles was demonstrated in elderly women
with osteoporosis, after 3 months of treatment (154). 
Recently, vitamin D analogs have been developed, that retain
the suppressive action on PTH and parathyroid gland growth,
but that have less calcemic and phosphatemic activity. Cur-
rently, two analogs, 19-nor-1,25-(OH)2D2 and 1α(OH)D2, are
being used for the treatment of secondary hyperparathyroidism
in the United States, and two are being used in Japan, 22-oxa-
calcitriol and 1,25-(OH)2-26,27F6D3 (155). Elucidation of the
mechanism of action for the different vitamin D analogs in the
next future will enhance our understanding of the vitamin D
pathway and improve their therapeutic uses in osteoporosis.
Conclusions
Vitamin D and calcium are important for normal skeletal growth
and for maintaining the mechanical and structural integrity of
the skeleton. Even though secure inferences from randomized
controlled trials on the prevention of osteoporotic fracture with
calcium and vitamin D supplementation are very limited, expe-
cially in women within the first years of menopause, these com-
pounds have been demonstrated to be pharmacologically ac-
tive, safe, and cost-effective for the prevention and treatment
of osteoporosis. Their use should therefore be encouraged,
particularly in the elderly as well as in other conditions of di-
etary deficiences. Moreover, over the last 30 years, several
clinical trials have reported the efficacy of vitamin D-hormone
analogs, calcitriol and alfacalcidiol, as possible additional ther-
apies for osteoporosis. In recent comparative studies as well
as in meta-analyses these compounds showed an overall in-
creased skeletal efficacy compared to plain vitamin D (104,
121, 132, 141, 142). However, their role in fracture prevention,
as well as their relative efficacy with respect to other treatment
regimens in osteoporosis (i.e. bisphosphonates), remain un-
der-investigated in long-term randomized controlled trials. Cer-
tainly, there is consistent and increasing evidence that treat-
ment with vitamin D analogs or calcium plus vitamin D supple-
mentation exert a synergistic effect with antiresorptive agents
on bone, and, thus, most patients will derive further benefit in
terms of fracture prevention from the addition of an antiresorp-
tive agent. 
Further studies will be needed to evaluate the relative impact
of different vitamin D formulations as well as the relative contri-
bution of calcium and vitamin D compounds on fracture pre-
vention. Interestingly, health effects of vitamin D and its ana-
logues may go beyond osteoporosis including prevention of
cancer, autoimmune diseases and diabetes, or improvement of
neuromuscular function (34, 35, 156-158).
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